2019-11-26T20:29:23-06:00 2019-03-31 ERNST & YOUNG US LLP 1901 6TH AVE N BIRMINGHAM AL 35203 990 2018-04-01 751835298 SUSAN G KOMEN BREAST CANCER FDN INC % Ria Williams SUSA 9728551600 5005 LBJ Freeway Suite 526 Dallas TX 752446125 Paula Sue Schneider President and CEO 9728551600 2019-11-22 KATHY PITTS P00292940 2052260027 2019-11-15 181.229.5.177 75306120193305000000 2019-11-26 P D7645E384763AEB8339B885771554B833BC3ADBE E29A02FADCAF5825D1E75B57BBFB9CE762992CE9 2018 2020-03-31 21:24:44Z SUSAN G KOMEN Paula Sue Schneider 5005 LBJ Freeway Suite 526 Dallas TX 752446125 138576137 false 7164 X www.komen.org X 1982 TX SUSAN G. KOMENFIGHTS BREAST CANCER ON ALL FRONTS BY DRIVING RSRCH,ADVOCATING FOR COMPASSIONATE PUBLIC POLICIES, PROVIDING TRUSTWORTHY INFO & SUPPORT PEOPLE FACING BREAST CANCER TODAY 13 13 248 2600 60395 51441732 63291987 14437717 12975072 14239081 15415716 -3380561 -1624976 76737969 90057799 28995790 29481585 0 0 21442628 22862266 1118493 2527973 13711290 31719529 37154373 83276440 92026197 -6538471 -1968398 201811514 192149996 77405059 75529111 124406455 116620885 X SUSAN G. KOMEN IS FIGHTING BREAST CANCER ON ALL FRONTS BY DRIVING RESEARCH BREAKTHROUGHS, ADVOCATING FOR COMPASSIONATE PUBLIC POLICIES, DELIVERING TRUSTWORTHY INFORMATION, AND PROVIDING CRITICAL SUPPORT TO PEOPLE FACING BREAST CANCER TODAY, HELPING THEM LIVE LONGER, HEALTHIER LIVES. false false 32 31327575 25620549 12446089 GRANTS TO RESEARCH INSTITUTIONS AND OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER RESEARCH PROJECTS INCLUDING THOSE FOCUSED ON THE BIOLOGY OF BREAST CANCER; EARLY DETECTION, DIAGNOSIS, AND PREVENTION STRATEGIES; DEVELOPING TARGETED THERAPIES, OVERCOMING BREAST CANCER PROGRESSION, TREATMENT RESISTANCE AND METASTASIS, PREDICTING RISK, DEVELOPING NEW IMAGING TECHNIQUES, AND UNDERSTANDING AND ADDRESSING DISPARITIES IN OUTCOMES AS WELL AS RESEARCH RESOURCES AND CONFERENCES. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 32 24622304 582735 875657 PROVISION OF BREAST HEALTH/CANCER EDUCATION RESOURCES & PATIENT SUPPORT PROGRAMS WERE MADE POSSIBLE DIRECTLY BY KOMEN AND THROUGH GRANTS TO OTHER NONPROFIT ORGANIZATIONS TO INCREASE THE PUBLIC'S KNOWLEDGE OF BREAST CANCER, ITS RISK FACTORS, THE IMPORTANCE OF EARLY DETECTION & SCREENING, KNOWING WHAT IS NORMAL FOR YOU, LIFESTYLE CHOICES, DIAGNOSIS AND TREATMENT, METASTATIC BREAST CANCER, CLINICAL TRIALS, SOCIAL SUPPORT, COMMUNICATION, COMPLEMENTARY AND INTEGRATIVE THERAPIES, AND COMMUNITY RESOURCES. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 32 5143857 3278301 0 GRANTS TO OTHER NONPROFIT ORGANIZATIONS TO SUPPORT BREAST CANCER SCREENING, DIAGNOSIS, AND TREATMENT PROGRAMS WITH A SPECIAL EMPHASIS ON PATIENT NAVIGATION, ESPECIALLY IN COMMUNITIES WHERE DISPARITIES IN OUTCOMES ARE SIGNIFICANT AND/OR ACCESS IS LIMITED. SEE SCHEDULE O FOR ADDITIONAL DETAILS. 61093736 true true false true false false false false false true true true false false false true false true false false true true false true true false false true false true false false false false false false false false true false false false false false false false false true 78 0 true 248 true true true false false false false true true false false false false false false X 13 13 false false false false false false false true true false true true true true true true true true true true false AL AK AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X Ria Williams 9728551600 5005 LBJ Freeway Suite 526 Dallas TX 75244 Peter D Brundage Chair of Board (Beg. 6/18) 1.0 0.0 X X 0 0 0 Michael B GreenwaldBEG 618 BOARD MEMBER AND TREASURER 1.0 0.0 X X 0 0 0 Connie O'Neill BOARD MEMBER FMR BOARD CHAIR (END 6/18) 1.0 0.0 X 0 0 0 Linda Custard BOARD MEMBER 1.0 0.0 X 0 0 0 Meghan Shannon BOARD MEMBER 1.0 0.0 X 0 0 0 Trish Wheaton BOARD MEMBER 1.0 0.0 X 0 0 0 Angela Zepeda BOARD MEMBER 1.0 0.0 X 0 0 0 Kim Bohr BOARD MEMBER 1.0 0.0 X 0 0 0 Andrew Robinson BOARD MEMBER 1.0 0.0 X 0 0 0 Kaye Ceille BOARD Member (BEG. 6/18) 1.0 0.0 X 0 0 0 Doug Knutson MD BOARD Member (BEG. 6/18) 1.0 0.0 X 0 0 0 Kristin Nimsger Board Member (Beg. 6/18) 1.0 0.0 X 0 0 0 Stephanie Stahl BOARD MEMBER (Beg. 6/18) 1.0 0.0 X 0 0 0 Dan Glennon End 618 Board Member and Treasurer 1.0 0.0 X X 0 0 0 Jane Abraham BOARD Member (End 6/18) 1.0 0.0 X 0 0 0 Alan Feld Board Member (End 6/18) 1.0 0.0 X 0 0 0 Dr Olufunmilayo Olopade Board Member (End 6/18) 1.0 0.0 X 0 0 0 Janet Dunn Frantz Board Member (End 6/18) 1.0 0.0 X 0 0 0 Melissa Maxfield Board Member (End 6/18) 1.0 0.0 X 0 0 0 Paula Schneider President and CEO 55.0 0.0 X 552025 0 7081 Catherine Olivieri Beg 319 VP, HR and Corporate Secretary 55.0 0.0 X 225406 0 45568 Dana Brown Beg 319 SVP CHIEF STRATEGY & OPS 55.0 0.0 X 44118 0 140 Ria Williams Beg 1018 Chief Financial Officer 55.0 0.0 X 181446 0 16424 Robert Green End 1018 Chief Financial Officer 55.0 0.0 X 309315 0 13027 Adam Vanek END 219 GEN. COUNSEL & CORPORATE SECY 55.0 0.0 X 245603 0 25485 Christina Alford SVP, Development 55.0 0.0 X 287093 0 23635 Victoria Wolodzko VP RESEARCH AND COM. HEALTH PR 55.0 0.0 X 228703 0 23240 Lori Maris SVP, Affiliate Network 55.0 0.0 X 188269 0 18100 Eric Montgomery VP, I.T. 55.0 0.0 X 198546 0 17621 Linda Fisk SVP, Marketing (BEG. 5/18) 55.0 0.0 X 161063 0 3779 Sue Aldana VP, Collaborative Revenue 55.0 0.0 X 163312 0 19864 Carrie Hodges Sr. Dir, ACC STR & Stewardship 55.0 0.0 X 177509 0 12556 Subhendu Rath Sr. Dir, IT Enterprise Systems 55.0 0.0 X 169182 0 29510 Vanessa Hewitt Sr. Dir., Internal Audit 55.0 0.0 X 163029 0 28776 Kimberly Sabelko Sr. Dir., Scientific Strategy 55.0 0.0 X 159567 0 27873 Ellen Willmott Former Officer 0.0 0.0 X 225255 0 15697 3679441 0 328376 51 true true false Event 360 205 N MICHIGAN AVE CHICAGO IL 60601 EVENT MANAGEMENT 5238270 STEPHEN THOMAS LTD 184 FRONT STREET EAST SUITE 501 TORONTO ONTARIO CA M5A 4N3 DIRECT MARKETING SVC 1964389 THE ADVERTISING COUNCIL inc 815 SECOND AVENUE 9TH FLOOR NEW YORK NY 10017 MARKETING 1182990 Wasserman Media Group LLC 10900 Wilshire Blvd Suite 1200 LOS ANGELES CA 90024 CONSULTING 550099 BLACKBAUD INC 6111 W PLANO PKWY STE 1000YC PLANO TX 75093 CONSULTING 540303 18 224516 15125344 47942127 167207 63291987 Affiliate Program Funding 900099 12975072 12975072 0 0 12975072 5202470 5202470 0 19231 19231 0 0 0 0 55650573 45437327 10213246 10213246 10213246 549746 15125344 3024262 -2474516 -2474516 0 0 0 0 44254 56749 -12495 -12495 Intercompany revenues 900099 449435 0 0 449435 Shared services income 900099 359169 359169 0 0 Other Income 900099 34200 0 60395 -26195 842804 90057799 13321746 60395 13383671 X 27311934 27311934 0 0 2169651 2169651 0 0 2815687 1005240 1336665 473782 0 0 0 0 16452459 5833744 7828105 2790610 655698 236521 312031 107146 1814136 593511 920148 300477 1124286 416047 513157 195082 0 0 0 0 168066 44819 54031 69216 309286 0 309286 0 232527 232527 0 0 2527973 2527973 193238 0 193238 0 3865 2223 966 676 3729462 1792238 946827 990397 9609107 5661994 200577 3746536 1816388 1180652 290622 345114 0 0 0 0 1063438 414106 504201 145131 1613882 714869 732185 166828 0 0 0 0 552188 391509 120277 40402 175 35 140 0 0 0 0 0 427562 79217 275582 72763 333755 166878 83439 83438 CONSULTING & PROF.SVCS. 10851269 9309593 1032401 509275 EVENT PRODUCTION 2920637 1987977 277112 655548 EQUIP. RENTAL & MAINT. 1406703 423225 848163 135315 Bank Fees 898851 517744 148187 232920 1023974 607482 293831 122661 92026197 61093736 17221171 13711290 X 35267442 20475918 640144 14151380 0 0 31040869 17950693 18645179 26578028 0 0 0 0 0 0 0 0 209655 217555 1215980 1410475 9431581 8498691 1168202 932890 101757276 77611324 47753580 67428258 0 0 0 0 20773 20773 201811514 192149996 6873683 8480242 70283876 66857399 247500 191470 0 0 0 0 0 0 0 0 0 0 0 0 77405059 75529111 X 86358517 67602118 37722938 48693767 325000 325000 124406455 116620885 201811514 192149996 X -1968398 -7539434 39999 0 0 1682263 X false true X true false X 77337857 105234559 55634984 51441732 63291987 352941119 0 0 77337857 105234559 55634984 51441732 63291987 352941119 42585598 310355521 3542123 2523145 2265964 5667273 5221701 19220206 0 0 0 0 0 0 153632 336857 51821 124523 34200 701033 372862358 90730880 0.83236 0.85794 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED X 46137 64115 186390 215154 232527 279269 74572499 144099673 74805026 144378942 1000000 1000000 250000 250000 1000000 1000000 1000000 1000000 4000000 6000000 218796 274215 253525 279269 1025805 250000 250000 250000 250000 1000000 1500000 66033 19341 19478 64115 168967 LOBBYING EXPENSES SCHEDULE C, PART II-A PUBLIC POLICY INITIATIVES HAVE THE POTENTIAL TO IMPACT PEOPLE TOUCHED BY BREAST CANCER. RECOGNIZING THE POWER OF ADVOCACY TO ACCOMPLISH ITS MISSION, KOMEN SUPPORTS LIMITED LOBBYING ACTIVITIES TO ACHIEVE EVIDENCE BASED POLICY AND LEGISLATIVE SOLUTIONS DESIGNED TO END BREAST CANCER FOREVER. 1362090 0 -4016 0 24267 204 1333603 1377855 0 10034 0 25799 0 1362090 1376069 1786 0 1377855 1346721 29808 460 1376069 1346267 4717 4263 1346721 0.75000 0.24000 0.01000 false false 0 0 0 610067 293736 316331 2475592 2232574 243018 6345922 5972381 373541 932890 Defensive equity fund 19773258 F Private Equity fund 47655000 F 67428258 0 0 X Intended use of endowment funds SCHEDULE D, PART V, LINE 4 KOMEN HAS THREE PERMANENT ENDOWMENTS: GOODMAN-BRINKER, FIRNBERG, AND A GENERAL ENDOWMENT. THE GOODMAN-BRINKER ENDOWMENT IS FOR BREAST CANCER RESEARCH FELLOWSHIPS, THE FIRNBERG ENDOWMENT IS FOR BREAST CANCER EDUCATIONAL PROGRAMS AND RESEARCH AWARDS, AND THE GENERAL ENDOWMENT'S EARNINGS ARE RESTRICTED FOR ORGANIZATIONAL MISSION ACTIVITIES. FIN 48 (ASC 740) FINANCIAL STATEMENT DISCLOSURE SCHEDULE D, PART X, LINE 2 THE ORGANIZATION IS SUBJECT TO A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE WERE NO UNCERTAIN TAX POSITIONS RECORDED IN THE CONSOLIDATED FINANCIAL STATEMENTS AT MARCH 31, 2019 OR MARCH 31, 2018. true East Asia and the Pacific 3 Grantmaking Research 339873 Central America and the Caribbean 2 Grantmaking Education 33104 Central America and the Caribbean 1 Grantmaking Screening 5000 Europe (Including Iceland and Greenland) 1 Program Services Legal Services 1449 Europe (Including Iceland and Greenland) 1 Grantmaking Education 75000 Europe (Including Iceland and Greenland) 10 Grantmaking Research 889080 North America 1 Grantmaking Education 120000 North America 2 Grantmaking Screening & Treatment 135756 North America 4 Grantmaking Research 492282 North America 1 Fundraising Direct Mail Processing 9817849 North America 4 Program Services Marketing Services 59625 North America 1 Program Services Software Maintenance 5242 South America 1 Grantmaking Education 1500 South America 1 Program Services Consulting 4651 Sub-Saharan Africa 1 Grantmaking Research 78056 North America 1 Program Services Consulting 3600 35 35 12062067 12062067 Central America and the Caribbean Screening Education Education Research Education Education Research Research Screening Research Research Screening Screening Research Research Research Treatment Research Education Research Research Education Research Education Research Research Research Research EDUCATION, TREATMENT RESEARCH RESEARCH, SCREENING, EDUCATION Treatment Research Research Education, Screening and Treatment Education Treatment Research Research Research Education Treatment Research Treatment Research Research Research Education and Treatment Treatment Research Research Research Research Research Research Treatment Research Education Research Treatment Education Research Research Education Research Research Research Research Research Research Education Treatment Research Research Treatment Screening and Treatment Research Education Education Treatment Education and Treatment Research Research Research Research Research Research Research Education Research Education, Screening, Treatment Research Education Edu 7104 WIRE TRANSFE North America Research 135756 WIRE TRANSFE Central America and the Caribbean Treatment 16000 WIRE TRANSFE Europe (Including Iceland and Greenland) RESEARCH 30000 WIRE TRANSFE North America Research 138750 WIRE TRANSFE North America Education 27100 WIRE TRANSFE East Asia and the Pacific Research 53781 WIRE TRANSFE North America Research 89854 WIRE TRANSFE Europe (including Iceland and Greenland) Education 126716 WIRE TRANSFE East Asia and the Pacific Research 149790 WIRE TRANSFE Europe (including Iceland and Greenland) Screening 149540 WIRE TRANSFE East Asia and the Pacific Research 75000 WIRE TRANSFE Central America and the Caribbean Treatment 10000 WIRE TRANSFE Sub-Saharan Africa Education 78056 WIRE TRANSFE Europe (including Iceland and Greenland) Education 36000 WIRE TRANSFE Europe (including Iceland and Greenland) Research 75000 WIRE TRANSFE Europe (including Iceland and Greenland) Research 81000 WIRE TRANSFE Europe (including Iceland and Greenland) Research 23760 WIRE TRANSFE Europe (including Iceland and Greenland) Research 158085 WIRE TRANSFE North America Research 49964 WIRE TRANSFE Europe (including Iceland and Greenland) Research 7978 WIRE TRANSFE Europe (including Iceland and Greenland) Research 36000 WIRE TRANSFE East Asia and the Pacific Research 61301 WIRE TRANSFE North America Education, Screening Treatment 66612 WIRE TRANSFE North America RESEARCH 120000 WIRE TRANSFE Europe (including Iceland and Greenland) Research 120000 WIRE TRANSFE North America EDUCATION 120000 WIRE TRANSFE Europe (Including Iceland and Greenland) EDUCATION 120000 WIRE TRANSFE 25 false false true false false false PROCEDURES FOR MONITORING USE OF GRANT FUNDS OUTSIDE OF THE UNITED STATES SCHEDULE F, PART I, LINE 2 AS OUTLINED IN EACH GRANT AGREEMENT, ALL GRANTEES ARE REQUIRED TO SUBMIT, AT A MINIMUM, ONE FINANCIAL AND PROGRESS REPORT WITHIN EACH YEAR OF THE GRANT TERM, AND ANY CHANGE REQUESTS THEY MAY HAVE FOR THEIR PROJECTS. ALL PROGRESS REPORTS AND REQUESTS ARE REVIEWED BY QUALIFIED STAFF. SEE SCHEDULE I, PART IV FOR MORE DETAILS. X X X X X X true EVENT 360 FUNDRAISING CONSULTING false 16586106 1309568 15276538 STEPHEN THOMAS LTD 184 FRONT STREET EAST SUITE 501 TORONTO ONTARIO CA M5A 4N3 DIRECT MARKETING false 12858860 785756 12073104 INFINITE AGENCY MARKETING CONSULTING false 2050109 164632 1885477 BOB CARTER COMPANIES FUNDRAISING CONSULTING false 15069 BLUE STATE DIGITAL INC FUNDRAISING CONSULTING false 70000 TURNKEY PROMOTIONS INC FUNDRAISING CONSULTING false 66377 RKD GROUP LLC FUNDRAISING CONSULTING false 40800 REVUNAMI INC FUNDRAISING CONSULTING false 36831 GROW FUNDRAISING CONSULTING INC FUNDRAISING CONSULTING false 3361 25190 -21829 CAUSEFORCE LLC FUNDRAISING CONSULTING false 13750 31498436 2527973 29213290 AL AK AZ AR CA CO CT DC FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX UT VT VA WA WV WI WY 3 Day 7 14353334 13980368 372966 11524 902892 907907 964519 DC Walk 1 839530 672945 166585 8204 51371 29701 3844 2 482226 472031 10195 54668 10201 26748 35000 17683 15675090 15125344 549746 74396 964464 964356 35000 986046 3024262 -2474516 SCHEDULE G PART I THE MAJORITY OF FUNDRAISING CONSULTING COSTS WITHOUT CORRESPONDING GROSS RECEIPTS ARE ASSOCIATED WITH KOMEN'S AFFILIATE NETWORK FUNDRAISING EFFORTS. THE GROSS RECEIPTS ARE RETAINED BY THE AFFILIATES. NET INCOME SUMMARY SCHEDULE G PART II Gross receipts are reduced by the amount of contributions, per IRS instructions. The contributions for fiscal year 2019 were $15,125,344. true African Women's Cancer Awareness Assoc 333 Cottman Avenue Philadelphia PA 19111 731704355 501c3 28321 Education Albany Medical College ATTN FRANCES ALBERT ALBANY NY 12208 141338310 501c3 150000 Research American Association for Cancer Research 615 CHESTNUT 17TH FL PHILADELPHIA PA 19106 236251649 501c3 90000 Research American Association on Health & Disabil 110 N WASHINGTON ST STE 328J ROCKVILLE MD 20850 521884887 501c3 84907 Research American Jewish Joint ATTN ITAI SHAMIR NEW YORK NY 100174014 131656634 501c3 83460 Education Arlington Free Clinic 2921 11TH STREET SOUTH ARLINGTON VA 22204 541671883 501c3 29999 Research Baylor College Medicine GRANTS ACCOUNTS RECEIVABLE HOUSTON TX 770303411 741613878 501c3 803148 RESEARCH Baylor University ONE BEAR PLACE 97043 WACO TX 767987043 741159753 501c3 150000 Research Beth Israel Deaconess Medical Center RESEARCH FINANCE OFFICE BR109 BOSTON MA 02215 042103831 501c3 149510 Research Black Nurses Rock 2519 W CHESTNUTE AVE ENID OK 73703 710609582 501c3 10000 EDUCATION Boat People SOS 60066 LEESBURG PIKE 100 FALLS CHURCH VA 02220 541563619 501c3 21027 TREATMENT Boston University EVENTS CONFERENCES BOSTON MA 02215 042103547 501c3 100000 RESEARCH Breast Care for Washington 4 ATLANTIC ST SW WASHINGTON DC 20032 455574713 501c3 30000 TREATMENT Brigham & Women's Hospital PO BOX 3149 BOSTON MA 022413149 042312909 501c3 255982 Research Broad Institute Inc 415 MAIN STREET CAMBRIDGE MA 02142 263428781 501c3 12000 Research Burnham Institute for Medical Research CANCER CTR LA JOLLA CA 92037 510197108 501c3 123111 RESEARCH Cancer Care 275 SEVENTH AVENUE NEW YORK NY 10001 131825919 501c3 2389297 EDUCATION AND TREATMENT CASA of Maryland Inc ATTN JENNIFER FREEDMAN HYATTSVILLE MD 20783 521372972 501c3 15000 TREATMENT Case Western Reserve University CONTROLLERS OFFICE CLEVELAND OH 441067006 341018992 501c3 177643 RESEARCH Children's Hospital Boston RESEARCH FINANCE BOSTON MA 022414413 042774441 501c3 48000 RESEARCH Cold Spring Harbor Laboratory ATTN WALTER GOLDSCHMIDTS COLD SPRING HARBOR NY 11724 112013303 501c3 48000 Education, Screening, Treatment Columbia University Medical Center 722 WEST 168TH STREET 4TH FL NEW YORK NY 10032 135598093 501c3 340000 Research Cornell University ATTN ILENE LAMBIASE ITHACA NY 14850 150532082 501c3 12000 Research Dana Farber Cancer Institute 450I BROOKLINE AVENUE BP 412 BOSTON MA 022155450 042263040 501c3 1412417 Research Doctors Community Hospital 8118 GOOD LUCK ROAD LANHAM MD 20706 521638026 501c3 40000 TREATMENT Duke University Medical Center ATTN MARY JOHNSON DURHAM NC 27701 560532129 501c3 378014 Research Eastern Michigan University ATTN SUSAN SHIPLEY YPSILANTI MI 48197 382953297 501c3 87500 EDUCATION Emory University Winship Cancer Inst PO BOX 935084 ATLANTA GA 311935084 580566256 501c3 150000 Research Ethiopian Community Development Council ATTN AZEB TADESSE ARLINGTON VA 22204 521308986 501c3 30000 TREATMENT Facing Our Risk of Cancer Empowered 16057 TAMPA PALMS BLVD W 373 TAMPA FL 33647 650927702 501c3 10000 EDUCATION Fox Chase Cancer Center' 333 COTTMAN AVENUE PHILADELPHIA PA 19111 232003072 501c3 90000 Research Fred Hutchinson Cancer Research Center PO BOX 19024 MS J6-330 SEATTLE WA 981091024 563744111 501c3 323500 Research Georgia Tech Research Corporation 505 TENTH STREET NW ATLANTA GA 30318 580603146 501c3 150000 Research H Lee Moffitt Cancer Center 12902 MAGNOLIA DRIVE TAMPA FL 33612 593238636 501c3 240000 Research Harvard Medical School HOLYOKE CENTER ROOM 600 CAMBRIDGE MA 02138 042103580 501c3 160000 RESEARCH Harvard University 25 SHATTUCK STREET BOSTON MA 02115 042103580 501c3 80000 Research Henry Ford Health System ONE FORD PLACE 5E DETROIT MI 48202 381357020 501c3 41092 Research Holy Cross Health ATTN ANNE GILLIS SILVER SPRING MD 20910 520738041 501c3 6380 EDUCATION Howard University 2041 GEORGIA AVENUE NW WASHINGTON DC 20060 530204707 501c3 29996 TREATMENT Indiana U (Indianapolis) FINANCIAL MGMT SERVICES INDIANAPOLIS IN 462666057 356001673 501c3 1230000 RESEARCH Johns Hopkins University 1650 ORLEANS STREET BALTIMORE MD 21231 520595110 501c3 2117480 RESEARCH Kingman Regional Medical Center 3269 STOCKTON HILL RD KINGMAN AZ 86409 742388735 501c3 7473 TREATMENT Korean Community Svc Ctr of Greater WA CTR OF GREATER WA ANNANDALE VA 22003 386005984 501c3 75231 SCREENING AND TREATMENT Leland Stanford Jr University PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501c3 120000 RESEARCH Living Beyond Breast Cancer ATTN JEAN SACHS CEO HAVERFORD PA 19041 530196932 501c3 24000 Education Maasai Wildernes Conservation Fund PO BOX 1413 SANTA BARBARA CA 93102 541943145 501c3 15000 EDUCATION Maricopa Health Foundation 2910 E CAMELBACK ROAD SUITE 180 PHOENIX AZ 85016 860777567 501c3 7500 TREATMENT Mary's Ctr for Maternal&Child Care Inc 2333 ONTARIO ROAD NW WASHINGTON DC 20009 521594116 501c3 88949 Education AND TREATMENT Massachusetts General Hospital PO BOX 414876 BOSTON MA 022414876 041564655 501c3 137681 Research Massachusetts Institute of Technology 160 MEMORIAL DRIVE CAMBRIDGE MA 02139 042103594 501c3 169077 RESEARCH Mayo Clinic Jacksonville GRIFFIN BUILDING ROOM 170 JACKSONVILLE FL 32224 593337028 501c3 200000 Research Mayo Clinic Rochester DBA MAYO CLINIC COLLEGE OF MEDICINE ROCHESTER MN 559034008 416011702 501c3 224000 Research Medical College of Wisconsin 1234 ANY STREET ANYWHERE TX 75244 390806261 501c3 150000 Research Memorial Sloan-Kettering Cancer Ctr 633 3RD AVENUE 28TH FL NEW YORK NY 10017 131924236 501c3 400000 RESEARCH Metastasis Research Society METASTASIS RESEARCH SOCIETY VESTAVIA HILLS AL 35242 251824374 501c3 33000 Research METAvivor Research and Support 312 SEVERN AVE W302 ANNAPOLIS MD 21403 371578088 501c3 20000 EDUCATION Mount Sinai School of Medicine SPONSORED PROJ ACTG NEW YORK NY 100296574 136171197 501c3 418779 RESEARCH Mountain Park Health Cntr ATTN KYLE MUNSON PHOENIX AZ 85012 860498020 501c3 22500 EDUCATION, SCREENING, TREATMENT National Black Nurses Association 8630 FENTON STREET SUITE 910 SILVER SPRING MD 20910 237194995 501c3 7000 Education National Minority Quality Forum Inc 1201 15TH ST NW SUITE 340 WASHINGTON DC 20005 311750942 501c3 50000 EDUCATION New York University School of Med ACCOUNTING/ACCOUNTS RECEIVABLE NEW YORK NY 10016 135562308 501c3 30000 RESEARCH North Carolina Central University 1801 FAYETTEVILLE STREET DURHAM NC 27707 566000730 501c3 81000 Research North Country Community Health Center 2920 N 4TH STREET FLAGSTAFF AZ 860041816 860663432 501c3 7500 TREATMENT Northwestern University - Chicago 633 CLARK EVANSTON IL 60208 362167817 501c3 389366 Research Nueva Vida Inc 2000 P STREET NW SUITE 300 WASHINGTON DC 20036 541943145 501c3 28634 TREATMENT Obesity Society 8757 GEORGIA AVENUE SILVER SPRING MD 20910 541438429 501c3 11000 Research Oregon Health & Science University SPONSORED PROGRAM ADMIN PORTLAND OR 97239 752668014 501c3 2183734 Research Partners for Cancer Care and Prevention 10 EAST LEE STREET UNIT 1901 BALTIMORE MD 21202 451605551 501c3 67500 SCREENING Princeton University 701 CARNEGIE CENTER PRINCETON NJ 08540 210634501 501c3 320000 Research Program for Appropriate PO BOX 900922 SEATTLE WV 98109 911157127 501c3 14246 EDUCATION Providence Health Foundation 1150 VARNUM ST NE WASHINGTOM DC 20017 521275583 501c3 14285 EDUCATION Providence Portland Medical Center 4805 NE GLISAN ST 5F40 PORTLAND OR 97213 930386906 501c3 30000 Research Purdue University SPONSORED PROGRAM SERVICES CHICAGO IL 606731235 356002041 501c3 150000 Research Regents of University of Michigan ROOM 7110 CCGC INTERNAL MEDICINE ANN ARBOR MI 481091274 386006309 501c3 12000 Research Research Advocacy Network 6505 WEST PARK BLVD PLANO TX 75093 566001393 501c3 47539 Research Rockefeller University ATTN SHAWN DAVIS NEW YORK NY 10065 131624158 501c3 90000 Research Roswell Park Alliance Foundation DEPARTMENT OF IMMUNOLOGY BUFFALO NY 14263 161391608 501c3 215794 Research Stanford University PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 501c3 335840 Research Stevens Institute of Technology 1 CASTLE POINT TERRACE HOBOKEN NJ 07030 221487354 501c3 36000 Research SUNY at Stony Brook ATTN JOANN DELUCIA-CONLON STONY BROOK NY 11794 146013200 501c3 299872 Research Temple University ATTN JEANNETTE WEST PASTELAK PHILADELPHIA PA 19122 231365971 501c3 36000 Research The Ohio State University College ATTN KATHY MILEM COLUMBUS OH 43205 316025986 501c3 75000 Research The Salk Institute ATTN CHRISTINE MARCKESE LA JOLLA CA 92037 376000511 501c3 100000 Research The University of Chicago RESEARCH ADMINISTRATION CHICAGO IL 60637 362177139 501c3 181000 Research The University of Toledo ATTN DR AMY THOMPSON TOLEDO OH 436063390 346401483 501c3 149958 Research The Vanderbilt University PMB 406310 NASHVILLE TN 372406310 620476822 501c3 112049 Research The Wistar Institute 3601 SPRUCE STREET PHILADELPHIA PA 04265 236434390 501c3 150000 Research Trustees of Columbia Univ SPONSORED PROJECTS FINANCE NEW YORK NY 10027 135598093 501c3 120000 Research Trustees of Dartmouth College OFFICE OF SPONSORED PROJECTS HANOVER NH 037551404 020222111 501c3 29999 Research Tulane University Health Sciences Center 800 E COMMERCE HARAHAN LA 70023 720423889 501c3 72000 Research Univ of Colorado Health Sciences Cent ATTN GEORGE JOHNSTON DENVER CO 802910238 846002597 501c3 150000 Research Univ of North Carolina at Chapel Hill 104 AIRORT DRIVE SUITE 2200 CB 1 CHAPEL HILL NC 275991350 566001393 501c3 1647977 EDUCATION, SCREENING, TREATMENT Univ of Texas MD Anderson Cancer Center GRANTS CONTRACTS HOUSTON TX 772104390 746001118 501c3 833173 Research University Miami School of Medicine ATTN MARIA A GARCIA CORAL GABLES FL 33146 590624458 501c3 30000 Research University of Alabama at Birmingham 1530 3RD AVENUE SOUTH BIRMINGHAM AL 352940111 636005396 501c3 27000 Research University of California at San Francis ANDREW BOULTER SAN FRANCISCO CA 94118 946036493 501c3 200000 Research University of California-Davis CASHIERS OFFICE WEST SACRAMENTO CA 957989062 956006143 501c3 35992 Research University of California-Los Angeles ADMINISTRATIVE MAIN CASHIER OFFICE LOS ANGELES CA 900959000 956006143 501c3 90000 Research University of California-San Diego USCD CASHIERS OFFICE LA JOLLA CA 92093 956006143 501c3 41999 Research University of California-San Francisco 1600 DIVISADERO ST BOX 1710 SAN FRANCISCO CA 94115 956006143 501c3 59999 Research University of Delaware 30 LOVETT AVENUE NEWARD DE 19716 516000279 501c3 90000 Research University of Illinois at Chicago PO BOX 20787 SPRINGFIELD IL 627080787 376000511 501c3 66938 RESEARCH University of Illinois--Urbana-Champaign GRANTS CONTRACTS POST AWARD SPRINGFIELD IL 10061 376000511 501c3 36000 Research University of Kansas Center for Research 2385 IRVING HILL ROAD LAWRENCE KS 66045 480680117 501c3 150000 Research University of Kansas Medical Center ATTN TIM SISKEY KANSAS CITY KS 66140 481108830 501c3 446888 Research University of Kentucky Research Fndn MARKEY CANCER CENTER LEXINGTON KY 405260001 616033693 501c3 90000 Research University of Massachusetts Amherst Goodell Bldg Room 405 Amherst MA 010033210 043167352 501c3 89549 Education, Treatment University of Miami School of Medicine Center for Cancer Prevention and Ge Miami FL 33136 590624458 501c3 36000 RESEARCH University of Michigan Alexandra Thebaud Ann Arbor MI 481091274 386006309 501c3 425969 Research University of Michigan Health Systems 3003 S State St Rm 1054 Ann Arbor MI 481091274 386006309 501c3 171067 RESEARCH University of Minnesota McNamara Alumni Center Minneapolis MN 554552070 416007513 501c3 80000 EDUCATION University of Notre Dame du Lac 731 Grace Hall Notre Dame IL 46556 350868188 501c3 179990 RESEARCH University of Pennsylvania Office of Research Services Philadelphia PA 191046205 231352685 501c3 779085 EDUCATION University of Pittsburgh Office of Research Pittsburgh PA 152132303 250966691 501c3 725296 RESEARCH University of South CarolinaThe 1600 Hampton Street Suite 404H Columbia SC 29208 576001153 501c3 135000 RESEARCH University of Southern California Attn Robert Osuna Los Angeles CA 900898001 951642394 501c3 234778 RESEARCH University of Texas at Health Science Center Elizabeth Frantz Houston TX 77030 741587488 501c3 135000 RESEARCH University of Utah 201 South Presidents Circle Room Salt Lake City UT 841129020 876000525 501c3 280000 RESEARCH University of Virginia at School of Medi PO Box 400195 Charlottesville VA 229044195 876000525 501c3 150000 RESEARCH University of Washington Attn Tami Sadusky Seattle WA 98105 916001537 501c3 260000 RESEARCH University of Wisconsin - Madison Research Sponsored Programs Madison WI 537151218 396006492 501c3 60000 RESEARCH UT HSC - San Antonio Office of Sponsored Programs San Antonio TX 772293900 741586031 501c3 475634 RESEARCH UT Southwestern Medical Center UT Southwestern Grants Mgmt Dallas TX 752841753 746000203 501c3 190000 RESEARCH Utah Cancer Control Program Attn Shari Watkins Salt Lake City UT 841144620 876000545 501c3 49962 SCREENING UTMD Anderson Cancer Ctr 1515 Holcombe Boulevard Unit 1644 Houston TX 770304009 746001118 501c3 174103 RESEARCH Vanderbilt University Medical Center Dept AT 40303 Atlanta GA 311920303 620476822 501c3 853242 RESEARCH Vermont Cancer Ctr UVM College of Med Attn Jennifer Gagnon Burlington VT 05405 030219309 501c3 104719 RESEARCH Vietnamese Resettlement Association Inc Attn Kim O Cook Falls Church VA 22044 541512549 501c3 19942 EDUCATION AND TREATMENT Virginia Commonwealth University Attn Presepine Fleming Richmond VA 23284 546001758 501c3 150000 RESEARCH Wake Forest University Health Sciences Grants Management WinstonSalem NC 27157 223849199 501c3 150000 RESEARCH Washington University at St Louis Scho 700 Rosedale Avenue Campus Box 103 Saint Louis MO 63112 430653611 501c3 104755 EDUCATION, RESEARCH Wayne State University Attn Julie Boerner Detroit MI 48201 366028429 501c3 60000 RESEARCH Weill Medical College of Cornell Univ 1300 York Avenue New York NY 10061 131623978 501c3 60000 RESEARCH Wesley Community Center 1300 S 10th Street Phoenix AZ 85034 860133770 501c3 7500 TREATMENT Whitehead Inst for Biomedical Research 9 Cambridge Center Cambridge MA 021421479 061043412 501c3 12000 RESEARCH Yale University 2 Whitney Avenue New Haven CT 06521 060646973 501c3 200000 RESEARCH 136 PROCEDURES FOR MONITORING THE USE OF GRANTS Schedule I, PART I, LINE 2 SUSAN G. KOMEN'S (KOMEN) POLICIES FOR MANAGING GRANTS FROM THE TIME OF PRE-AWARD THROUGH CLOSEOUT ARE DESIGNED TO MAXIMIZE FLEXIBILITY WHILE MAINTAINING A HIGH STANDARD OF ACCOUNTABILITY AND PRESERVING THE INTEGRITY OF THE REVIEW AND AWARD PROCESS. KOMEN REQUIRES ALL GRANTEES TO SIGN A GRANT AGREEMENT SETTING FORTH THE TERMS OF THE GRANT, INCLUDING: PURPOSE, AMOUNT, BUDGETARY RESTRICTIONS, DURATION, PAYMENT SCHEDULE, REPORTING REQUIREMENTS, AUDIT, AND EARLY TERMINATION RIGHTS. FOR RESEARCH GRANTS, SCIENTIFIC PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED THROUGHOUT THE GRANT TERM BY A PH.D. OR MASTERS-LEVEL RESEARCH GRANT MANAGER. FOR EDUCATION, SCREENING, AND TREATMENT GRANTS, PROGRESS AND FINANCIAL OVERSIGHT IS MONITORED OR SUPERVISED THROUGHOUT THE GRANT TERM BY QUALIFIED PROFESSIONALS SERVING AS GRANTS MANAGERS. EACH YEAR OF THE GRANT TERM, GRANTEES ARE REQUIRED TO SUBMIT PROGRESS AND FINANCIAL REPORTS DETAILING PROGRESS TOWARD AIMS AND OBJECTIVES, MAJOR ACCOMPLISHMENTS, KEY DELIVERABLES AND CHALLENGES ENCOUNTERED, WITH A FULL ACCOUNTING OF GRANT FUNDS EXPENDED (ACTUAL VERSUS BUDGETED EXPENSES) AND WRITTEN JUSTIFICATION OF EXPENSES. AS APPROPRIATE, THE GRANTS MANAGER MAY CONDUCT SITE VISITS WITH GRANTEES TO GAIN A BETTER UNDERSTANDING OF THEIR WORK AND ADDRESS ANY CHALLENGES IMPACTING THE FUNDED PROGRAM. ALL GRANT FUNDS MUST BE EXPENDED IN ACCORDANCE WITH THE PROJECT'S APPROVED BUDGET AND ARE DISBURSED IN ACCORDANCE WITH THE SCHEDULE DOCUMENTED WITHIN THE GRANT AGREEMENT. REQUESTS FOR CHANGES TO THE DESIGN OF THE FUNDED PROJECT OR BUDGET ARE SUBJECT TO PRIOR APPROVAL BY KOMEN IN ACCORDANCE WITH THE TERMS OF THE GRANT AGREEMENT. AS PART OF ITS OVERSIGHT PRACTICES, THE TERMS OF THE GRANT AGREEMENT MAY PROVIDE KOMEN WITH, AMONG OTHER THINGS, THE RIGHT TO REQUEST WITH REASONABLE PRIOR NOTICE TO THE GRANTEE: (1) ADDITIONAL PROGRESS AND/OR FINANCIAL REPORTING FROM THE GRANTEE, (2) GRANTEE PARTICIPATION IN SITE VISITS, TELEPHONE CONFERENCES, PRESENTATIONS, OR OTHER SPEAKING ENGAGEMENTS, AND (3) WITH PRIOR WRITTEN NOTICE, ADJUSTMENT TO THE PROJECT REPORTING PERIOD AND ASSOCIATED DISBURSEMENT OF GRANT FUNDS AT ANY TIME DURING THE GRANT TERM. X true true X X X X X X true false false false false false false false false Paula Schneider President and CEO 546901 0 0 0 5124 0 0 0 7081 0 559106 0 0 0 Catherine Olivieri Beg 319 VP, HR and Corporate Secretary 221648 0 0 0 3758 0 14137 0 31431 0 270974 0 0 0 Ria Williams Beg 1018 Chief Financial Officer 179382 0 0 0 2064 0 8586 0 7838 0 197870 0 0 0 Robert Green End 1018 Chief Financial Officer 271798 0 22121 0 15396 0 9040 0 3987 0 322342 0 0 0 Adam Vanek END 219 GEN. COUNSEL & CORPORATE SECY 243233 0 0 0 2370 0 0 0 25485 0 271088 0 0 0 Christina Alford SVP, Development 284993 0 0 0 2100 0 16414 0 7221 0 310728 0 0 0 Victoria Wolodzko VP RESEARCH AND COM. HEALTH PR 226401 0 0 0 2302 0 11131 0 12109 0 251943 0 0 0 Lori Maris SVP, Affiliate Network 185646 0 0 0 2623 0 7616 0 10484 0 206369 0 0 0 Eric Montgomery VP, I.T. 196541 0 0 0 2005 0 7792 0 9829 0 216167 0 0 0 Linda Fisk SVP, Marketing (BEG. 5/18) 130039 0 25000 0 6024 0 0 0 3779 0 164842 0 0 0 Sue Aldana VP, Collaborative Revenue 159647 0 0 0 3665 0 4592 0 15272 0 183176 0 0 0 Carrie Hodges Sr. Dir, ACC STR & Stewardship 175738 0 0 0 1771 0 10638 0 1918 0 190065 0 0 0 Subhendu Rath Sr. Dir, IT Enterprise Systems 167313 0 0 0 1869 0 10195 0 19315 0 198692 0 0 0 Vanessa Hewitt Sr. Dir., Internal Audit 161167 0 0 0 1862 0 10151 0 18625 0 191805 0 0 0 Kimberly Sabelko Sr. Dir., Scientific Strategy 157063 0 0 0 2504 0 9401 0 18472 0 187440 0 0 0 Ellen Willmott Former Officer 90322 0 133754 0 1179 0 5484 0 10213 0 240952 0 0 0 FORM 990, SCHEDULE J, PART I, LINE 1A SUPPLEMENTAL COMPENSATION INFORMATION ONE TRIP DURING FY19 INCLUDED FIRST CLASS AIR FARE. ALL OTHER REIMBURSED TRAVEL EXPENSES DO NOT INCLUDE FIRST CLASS AIR FARE EXCEPT AS MAY BE APPROVED IN ADVANCE FOR MEDICAL ACCOMMODATION. HOWEVER, PERSONAL FREQUENT FLIER MILEAGE AND COUPONS MAY BE USED FOR NO COST UPGRADES. IN THE EVENT OF INTERNATIONAL TRAVEL WITH FLIGHT TIMES OF SIX HOURS OR MORE, AND PRE-APPROVAL, BUSINESS OR FIRST CLASS TRAVEL MAY BE PERMITTED IF THERE IS A MEDICAL ACCOMMODATION OR BUSINESS PURPOSE. WHENEVER POSSIBLE, DISCOUNTED FIRST CLASS AND UPGRADES ARE USED TO MINIMIZE COSTS. SEVERANCE PAYMENT FORM 990, SCHEDULE J, PART I, LINE 4A ROBERT GREEN RECEIVED A SEVERANCE PAYMENT OF $22,121. ELLEN WILLMOTT RECEIVED A SEVERANCE PAYMENT OF $133,754. X 73616 FMV X 1 841 FMV X 3 22375 FMV X 3 20875 FMV X Gift cards 5 23550 fmv X Event venue 1 25950 fmv false true false SCHEDULE M, PART I, COLUMN (B) THE AMOUNTS IN THIS COLUMN REPRESENTS THE NUMBER OF ITEMS CONTRIBUTED OTHER THAN FOOD, WHICH IS NUMBER OF CONTRIBUTIONS. FORM 990, PART I, QUESTION 6 - VOLUNTEERS VOLUNTEERS SERVE IN A VARIETY OF WAYS, BUT THE GREATEST NUMBERS OF VOLUNTEERS ASSIST WITH THE SUSAN G. KOMEN 3 DAY SERIES. FORM 990, PART III - PROGRAM SERVICE ACCOMPLISHMENTS SUSAN G. KOMEN IS A LEADING GLOBAL BREAST CANCER ORGANIZATION, HAVING FUNDED MORE BREAST CANCER RESEARCH THAN ANY OTHER NONPROFIT OUTSIDE THE U.S. GOVERNMENT WHILE PROVIDING REAL TIME HELP TO THOSE FACING THE DISEASE. SINCE ITS FOUNDING IN 1982, KOMEN HAS FUNDED MORE THAN $1 BILLION IN BREAST CANCER RESEARCH AND PROVIDED OVER $2.3 BILLION IN FUNDING FOR PATIENT NAVIGATION, SCREENING, DIAGNOSIS, TREATMENT, EDUCATION, HEALTH SYSTEMS IMPROVEMENT, AND PSYCHOSOCIAL SUPPORT PROGRAMS SERVING MILLIONS OF PEOPLE IN MORE THAN 60 COUNTRIES WORLDWIDE. KOMEN WAS FOUNDED BY NANCY G. BRINKER, WHO PROMISED HER SISTER, SUSAN G. KOMEN, THAT SHE WOULD END THE DISEASE THAT CLAIMED SUZY'S LIFE. RESEARCH SINCE ITS FOUNDING IN 1982, KOMEN'S RESEARCH INVESTMENTS HAVE CONTRIBUTED TO MANY MAJOR ADVANCES IN BREAST CANCER SCIENCE. THE PROGRESS HAS BEEN SIGNIFICANT - TODAY, WE KNOW THAT BREAST CANCER IS MORE THAN A SINGLE DISEASE. WE HAVE A BETTER UNDERSTANDING OF THE GENETICS OF BREAST CANCER AND THE CRITICAL NEED TO TAILOR SCREENING, DIAGNOSIS, TREATMENT, AND PREVENTION STRATEGIES TO INDIVIDUALS THROUGH ADVANCES IN PRECISION MEDICINE. KOMEN'S RESEARCH PROGRAMS ARE FOCUSED ON BREAKTHROUGH RESEARCH TO PREVENT AND CURE BREAST CANCER THROUGH BETTER APPROACHES FOR EARLY DETECTION AND DIAGNOSIS, UNDERSTANDING METASTASIS AND RECURRENCE, AND DEVELOPING NOVEL THERAPIES FOR ALL STAGES OF BREAST CANCER, WITH THE GOAL OF SUPPORTING WORK THAT HAS SIGNIFICANT POTENTIAL TO LEAD TO NEW TREATMENTS AND TECHNOLOGIES THAT WILL REDUCE THE NUMBER OF BREAST CANCER DEATHS IN THE U.S. BY 50 PERCENT BY 2026. KOMEN'S RESEARCH PROGRAMS ARE GUIDED BY 67 OF THE WORLD'S LEADERS IN BREAST CANCER RESEARCH, ONCOLOGY AND ADVOCACY. THE SCIENTIFIC ADVISORY BOARD ASSISTS KOMEN IN SETTING ITS RESEARCH STRATEGY AND PRIORITIZING ITS RESEARCH INVESTMENT. THE KOMEN SCHOLARS LEAD AND PARTICIPATE IN KOMEN'S WORLD-CLASS SCIENTIFIC PEER REVIEW PROCESS. OUR ADVOCATES IN SCIENCE BRING THE COLLECTIVE PATIENT VOICE TO KOMEN'S RESEARCH PROGRAMS AND SCIENTIFIC ACTIVITIES, EMPHASIZING URGENCY AND PATIENT IMPACT. KOMEN AWARDS GRANTS TO INDIVIDUAL SCIENTISTS, RESEARCH TEAMS, AND ORGANIZATIONS AROUND THE WORLD THROUGH A FAIR, TRANSPARENT, RIGOROUS, AND COMPETITIVE REVIEW PROCESS THAT ENSURES MAXIMUM IMPACT FOR OUR RESEARCH INVESTMENT. IN FY19, KOMEN AWARDED 60 GRANTS THROUGH ITS RESEARCH PROGRAMS TO SUPPORT SCIENTIFIC RESEARCH, COLLABORATIONS AND TRAINING IN THE UNITED STATES AND OTHER COUNTRIES, INCLUDING: AUSTRALIA, CANADA, FRANCE, ITALY, AND SOUTH AFRICA. WE HAVE A STRONG COMMITMENT TO SUPPORTING THE NEXT GENERATION OF LEADERS IN BREAST CANCER RESEARCH. SUSTAINING THE WORKFORCE IS CRITICAL; WE WANT TO UNLEASH THEIR CREATIVITY AND INNOVATION TO DRIVE DISCOVERY. THE PUBLIC CANNOT AFFORD TO LOSE PROMISING EARLY CAREER INVESTIGATORS DUE TO A LACK OF FUNDING OPPORTUNITIES. TO THAT END, KOMEN AWARDED CAREER CATALYST RESEARCH GRANTS TO SUPPORT EARLY CAREER INVESTIGATORS IN BREAST CANCER RESEARCH IN THEIR EFFORTS TO CONQUER METASTASIS. KOMEN ALSO AWARDED GRADUATE TRAINING IN DISPARITIES RESEARCH COMPETITIVE RENEWAL GRANTS TO SUPPORT TRAINING LEADERS IN THE FIELD OF BREAST CANCER DISPARITIES RESEARCH. KOMEN ALSO OFFERED LEADERSHIP GRANTS TO SUPPORT KEY WORK BY LEADERS IN THE FIELD OF BREAST CANCER RESEARCH. EACH MECHANISM IS DESCRIBED BELOW. CAREER CATALYST RESEARCH GRANTS (CCR): CCR GRANTS PROVIDE UNIQUE OPPORTUNITIES FOR SCIENTISTS WHO HAVE HELD FACULTY POSITIONS FOR NO MORE THAN 5 YEARS AT THE TIME OF APPLICATION TO ACHIEVE RESEARCH INDEPENDENCE. THE GOAL OF THE FY19 CCR GRANTS IS TO SUPPORT OUTSTANDING TRANSLATIONAL RESEARCH FOCUSED ON THE UNDERSTANDING, DETECTION, AND TREATMENT OF METASTATIC BREAST CANCER WHICH WILL LEAD TO A REDUCTION IN BREAST CANCER DEATHS BY 2026. GRADUATE TRAINING IN DISPARITIES RESEARCH - COMPETITIVE RENEWAL GRANTS (GTDR-CR): GTDR-CR GRANTS PROVIDES FUNDING TO OUTSTANDING PROGRAMS TO ESTABLISH AND/OR SUSTAIN INNOVATIVE TRAINING PROGRAMS FOR GRADUATE STUDENTS SEEKING CAREERS DEDICATED TO ACHIEVING HEALTH EQUITY. THE GOAL OF THE FY19 COMPETITIVE RENEWAL IS TO SUPPORT PROGRAMS FOR AN ADDITIONAL YEAR TO MAINTAIN SUCCESSFUL PROGRAMS THAT ARE WORKING TOWARDS ACHIEVING KOMEN'S BOLD GOAL. LEADERSHIP GRANTS: LEADERSHIP GRANTS PROVIDE SUPPORT FOR HYPOTHESIS-DRIVEN RESEARCH PROJECTS CONDUCTED BY THE DISTINGUISHED BREAST CANCER RESEARCHERS AND CLINICIANS WHO SERVE AS KOMEN'S SCIENTIFIC ADVISORS AND SEEK TO DISCOVER AND DELIVER THE CURES FOR BREAST CANCER. OPPORTUNITY GRANTS / STRATEGIC PARTNERSHIP AND PROGRAM GRANTS (OG/SPP): OG AND SPP GRANTS SUPPORT SPECIAL RESEARCH PROJECTS, PROGRAMS, AND COLLABORATIONS THAT LEVERAGE RESEARCH AND COMMUNITY RESOURCES TO FACILITATE THE DEVELOPMENT OF THE INFRASTRUCTURE, TOOLS, AND OTHER MEANS TO ACCELERATE THE TRANSLATION OF SCIENTIFIC DISCOVERIES FROM BENCH TO BEDSIDE TO CURBSIDE. FUNDING FROM ORGANIZATIONS LIKE KOMEN AND ITS SUPPORTERS HAS PROVEN CRITICAL FOR ALL THESE ACTIVITIES, PARTICULARLY FOR CANCER RESEARCH AND FOR CLINICAL TRIALS. KOMEN'S RESEARCH INVESTMENT THROUGH THESE GRANT MECHANISMS SUPPORTS PROJECTS THAT AIM TO, AMONG OTHER THINGS: (A) DEVELOP NOVEL TREATMENT STRATEGIES FOR METASTATIC DISEASE; (B) CREATE NEW STRATEGIES TO DETECT AND PREVENT RECURRENCE; (C) OVERCOME TREATMENT RESISTANCE; (D) UNDERSTAND AND ADDRESS DISPARITIES IN OUTCOMES; (E) ACCELERATE MEDICAL DISCOVERY AND DELIVERY USING DATA SCIENCE; AND (F) BUILDING ESSENTIAL TOOLS AND RESOURCES TO DRIVE SCIENTIFIC DISCOVERY. EXAMPLES OF RESEARCH GRANTS AWARDED IN FY19 INCLUDE: (A) DEVELOP NOVEL TREATMENT STRATEGIES FOR METASTATIC BREAST CANCER: JOE GRAY, PH.D., OF OREGON HEALTH & SCIENCE UNIVERSITY, WAS AWARDED A LEADERSHIP GRANT TO IMPROVE THE TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER. HE WILL IDENTIFY FDA-APPROVED DRUGS THAT COULD INCREASE THE EFFICACY OF IMMUNE THERAPIES AND THEN TEST THOSE DRUGS IN PRECLINICAL MODELS. THE GOAL OF THIS STUDY IS TO BETTER INFORM THERAPEUTIC STRATEGIES FOR THESE PATIENTS BY ENHANCING THE IMMUNE SYSTEM'S ABILITY TO KILL THE CANCER CELLS. (B) CREATE NEW STRATEGIES TO DETECT AND PREVENT RECURRENCE ERIC WINER, M.D., OF DANA-FARBER CANCER INSTITUTE, WAS AWARDED A LEADERSHIP GRANT TO IDENTIFY NEW RISK FACTORS OF LATE RECURRENCE OF ESTROGEN RECEPTOR-POSITIVE (ER+) BREAST CANCER. DR. WINER WILL EXAMINE THE IMPACT OF RISK FACTORS SUCH AS BMI, POST-DIAGNOSIS WEIGHT GAIN, POST-DIAGNOSIS PHYSICAL ACTIVITY, AND DIET ON LATE RECURRENCE AND IDENTIFY POTENTIAL THERAPEUTIC INTERVENTIONS. (C) OVERCOME TREATMENT RESISTANCE: AKI MORIKAWA, M.D., PH.D, OF UNIVERSITY OF MICHIGAN, WAS AWARDED A CAREER CATALYST RESEARCH GRANT TO STUDY WAYS TO IMPROVE TREATMENT RESPONSE FOR BREAST CANCER PATIENTS THAT HAVE DEVELOPED BRAIN METASTASES. DR. MORIKAWA WILL TEST THE EFFECTIVENESS OF A LARGE PANEL OF DRUGS ON BRAIN METASTASES SAMPLES FROM PATIENTS. THE GOAL IS TO DETERMINE IF REAL-TIME DRUG TESTING CAN GUIDE TREATMENT DECISIONS IN THE CLINIC AND IMPROVE OUTCOMES FOR BREAST CANCER PATIENTS WHO DEVELOP BRAIN METASTASES. (D) UNDERSTAND AND ADDRESS DISPARITIES IN OUTCOMES: LAUREN MCCULLOUGH, PH.D., OF EMORY UNIVERSITY, WAS AWARDED A CAREER CATALYST RESEARCH GRANT TO IDENTIFY CONTRIBUTORS TO POOR OUTCOMES IN A LARGE DIVERSE POPULATION IN GEORGIA, INCLUDING SOCIOECONOMIC FACTORS, URBAN/RURAL BARRIERS AND RACIAL/ETHNIC FACTORS WHICH CAN ALL LEAD TO DIFFERENCES IN BREAST CANCER METASTASIS OUTCOMES. HER TEAM WILL WORK TO UNDERSTAND WHY THESE DISPARITIES EXIST AND INFORM FUTURE THERAPEUTIC, BEHAVIORAL AND POLICY INTERVENTIONS TO IMPROVE OUTCOMES IN MARGINALIZED POPULATIONS. MELINA ARNOLD, PH.D., OF THE INTERNATIONAL AGENCY FOR RESEARCH ON CANCER, WAS AWARDED A CAREER CATALYST RESEARCH GRANT TO CONDUCT THE FIRST INTERNATIONAL STUDY TO DETERMINE THE TRUE BURDEN OF METASTATIC BREAST CANCER AMONG HIGH-INCOME COUNTRIES. USING POPULATION-BASED DATA AND CANCER REGISTRIES, DR. ARNOLD WILL DETERMINE IF THERE ARE DIFFERENCES IN SURVIVAL OF WOMEN WITH METASTATIC BREAST CANCER ACROSS COUNTRIES AND IDENTIFY FACTORS THAT CONTRIBUTE TO DIFFERENCES IN OUTCOMES. THIS INFORMATION WILL BE USED TO CREATE RECOMMENDATIONS TO HELP ADDRESS METASTATIC BREAST CANCER DISPARITIES AND IMPROVE OUTCOMES. (E) ACCELERATE MEDICAL DISCOVERY AND DELIVERY USING DATA SCIENCE: REGINA BARZILAY, PH.D., OF THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY, WAS AWARDED A LEADERSHIP GRANT TO DEVELOP AN ACCURATE RISK ASSESSMENT MODEL TO PREDICT PATIENTS AT HIGH RISK OF DEVELOPING PRIMARY BREAST CANCER. DR. BARZILAY WILL USE A LARGE COLLECTION OF PATIENTS' MAMMOGRAPH IMAGES WITH KNOWN OUTCOMES TO TEACH MACHINES (ARTIFICIAL INTELLIGENCE) TO IDENTIFY FEATURES THAT PREDICT BREAST CANCER RISK. OVERALL, THE GOAL OF THIS PROJECT IS TO IMPROVE EARLY DETECTION OF BREAST CANCER BY IDENTIFYING WOMEN AT HIGH RISK WHO MIGHT BENEFIT FROM A MORE PERSONALIZED BREAST CANCER SCREENING PROGRAM. MIA LEVY, M.D., OF RUSH UNIVERSITY MEDICAL CENTER WAS AWARDED A LEADERSHIP GRANT TO DEVELOP NOVEL DOCUMENTATION AND REPORTING STRATEGIES WITHIN THE PATIENT ELECTRONIC HEALTH RECORD THAT WOULD ALLOW FOR COLLECTION AND REPORTING OF OUTCOMES RELATED TO THE MANAGEMENT OF ADJUVANT ENDOCRINE THERAPY (AET), DEFINED AS LEARNING HEALTHCARE SYSTEM (LHS). THE ULTIMATE GOAL OF THIS STUDY IS TO IMPLEMENT THE LHS AND CHANGE HEALTHCARE DELIVERY FOR PATIENTS WITH BREAST CANCER, DECREASING RATES OF RECURRENCE AND DEATH FROM BREAST CANCER. (F) BUILDING ESSENTIAL TOOLS AND RESOURCES TO DRIVE SCIENTIFIC DISCOVERY JOHNS HOPKINS UNIVERSITY WAS AWARDED A SPONSORED PROGRAMS GRANT TO SUPPORT THE TRANSLATIONAL BREAST CANCER RESEARCH CONSORTIUM (TBCRC). THE TBCRC IS A COLLABORATION OF 19 CLINICAL SITES THAT WORK TOGETHER TO CONDUCT INNOVATIVE, HIGH-IMPACT, BIOLOGICALLY-DRIVEN TRANSLATIONAL AND CLINICAL RESEARCH TO IMPROVE OUTCOMES FOR BREAST CANCER PATIENTS. SINCE 2006, THE TBCRC HAS DEVELOPED 50 CLINICAL TRIALS, ABOUT HALF OF WHICH HAVE FOCUSED ON METASTATIC BREAST CANCER, DRUG RESISTANCE AND/OR RECURRENCE. TBCRC FINDINGS HAVE BEEN REPORTED IN OVER 80 SCIENTIFIC PEER REVIEWED PUBLICATIONS AND PRESENTATIONS TO DATE, INCLUDING 8 JOURNAL ARTICLES, AND 10 POSTER PRESENTATIONS, 3 POSTER DISCUSSIONS AND 1 TALK AT SCIENTIFIC CONFERENCES IN FY19. THE SUSAN G. KOMEN TISSUE BANK AT THE INDIANA UNIVERSITY SIMON CANCER CENTER (KTB), WAS AWARDED A SPONSORED PROGRAMS GRANT TO SUPPORT THE WORLD'S ONLY BIOREPOSITORY OF HEALTHY BREAST TISSUE. THE KTB COLLECTS AND STORES HEALTHY TISSUE AND BLOOD SAMPLES FROM DIVERSE POPULATIONS OF WOMEN REPRESENTING THE ENTIRE CONTINUUM OF BREAST DEVELOPMENT FROM PUBERTY TO MENOPAUSE. THE SAMPLES CAN BE UTILIZED BY RESEARCHERS WORLDWIDE TO STUDY BREAST ONCOGENESIS (WHEN CANCER FORMS AND NORMAL CELLS ARE TRANSFORMED INTO CANCER CELLS). SINCE ITS FOUNDING IN 2007, THE KTB HAS COLLECTED BREAST TISSUE SPECIMENS FROM MORE THAN 5,000 HEALTHY DONORS AND BLOOD FROM OVER 11,000 INDIVIDUALS. TO DATE, KTB'S RESOURCES HAVE LED TO 44 SCIENTIFIC PEER REVIEWED PUBLICATIONS, INCLUDING 5 JOURNAL ARTICLES IN FY19. EDUCATION AND PATIENT SUPPORT: KOMEN IS A TRUSTED SOURCE OF BREAST CANCER INFORMATION FOR PEOPLE ALL OVER THE WORLD AND IS INSTRUMENTAL IN CONNECTING PEOPLE WITH THE RESOURCES THEY NEED IN THEIR FIGHT AGAINST BREAST CANCER. OUR WEBSITE, KOMEN.ORG, PROVIDES CURRENT, SAFE, ACCURATE, COMPREHENSIVE, AND UNBIASED INFORMATION ABOUT BREAST CANCER, BASED ON SCIENTIFIC EVIDENCE. CONTENT IS OFFERED IN A VARIETY OF FORMATS INCLUDING INTERACTIVE VIDEO USING ANIMATION AND VOICEOVER IN ENGLISH AND SPANISH, ILLUSTRATIONS, CHARTS, GRAPHS, AND SHORT VIDEOS TO MEET THE LEARNING PREFERENCES AND NEEDS OF OUR WEB VISITORS. THE "ABOUT BREAST CANCER" SECTION OF KOMEN'S WEBSITE, CO-DEVELOPED WITH HARVARD MEDICAL SCHOOL FACULTY AND DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER STAFF, RECEIVED MORE THAN 5.5 MILLION PAGE VIEWS DURING FY19. KOMEN ALSO PROVIDES EVIDENCE-BASED, EASY-TO-READ EDUCATIONAL MATERIALS IN DOWNLOADABLE FORMATS ON KOMEN.ORG. EXAMPLES OF KOMEN EDUCATIONAL MATERIALS INCLUDE: A) BREAST SELF-AWARENESS MESSAGE CARDS IN MORE THAN 40 LANGUAGES, B) BREAST CANCER SPECIFIC BROCHURES AND FACTSHEETS, C) BOOKLETS WITH SUPPORT INFORMATION FOR SURVIVORS AND CO-SURVIVORS, AND D) TOOLKITS FOR BREAST CANCER OUTREACH AND EDUCATION FOR HISPANIC/LATINO IN ENGLISH AND SPANISH AND FOR BLACK AND AFRICAN-AMERICAN COMMUNITIES. THE SUSAN G. KOMEN "1-877 GO KOMEN" (1-877-465-6636) BREAST CARE HELPLINE OFFERS BREAST CANCER EDUCATION, PSYCHOSOCIAL SUPPORT, AND INFORMATION ABOUT COMMUNITY RESOURCES FOR PATIENTS, FAMILIES, AND FRIENDS. THE CLINICAL TRIAL INFORMATION HELPLINE PROVIDES INFORMATION, RESOURCES, COACHING AND SUPPORT RELATED TO BREAST CANCER CLINICAL TRIALS. THE HELPLINE OPERATES FROM 9 A.M. - 10 P.M. E.T. THE SERVICE IS OFFERED IN ENGLISH, SPANISH, AND TAGALOG. DURING FY19, THE KOMEN HELPLINE RESPONDED TO MORE THAN 15,000 CALLS AND EMAILS. IN ADDITION, IN FY19 KOMEN PARTNERED WITH LIVING BEYOND BREAST CANCER TO DEVELOP AND DELIVER A CONFERENCE FOR WOMEN LIVING WITH METASTATIC BREAST CANCER IN THE WASHINGTON, D.C. REGION. THE CONFERENCE BRINGS PEOPLE WITH METASTATIC BREAST CANCER, CAREGIVERS, HEALTHCARE PROFESSIONALS, HEALTHCARE ORGANIZATIONS, SUPPORT ORGANIZATIONS AND OTHERS, WHO PARTICIPATE IN THE CARE OF PATIENTS WITH METASTATIC BREAST CANCER, TO DISCUSS SCIENTIFIC BREAKTHROUGHS, ONGOING CLINICAL TRIALS, QUALITY OF LIFE, AND INTEGRATIVE MEDICINE. THE CONFERENCE IS DESIGNED TO FILL THE NEEDS OF THE METASTATIC BREAST CANCER COMMUNITY AND SEEKS TO STRENGTHEN METASTATIC BREAST CANCER VOICES IN THE NATIONAL CAPITAL REGION BY CREATING OPPORTUNITIES FOR LEARNING, ENGAGEMENT AND ACTION. BREAST CANCER IS THE MOST COMMON CANCER IN WOMEN, WORLDWIDE, AND THE NUMBER OF CASES IS INCREASING IN NEARLY EVERY COUNTRY. THE NUMBER OF NEW BREAST CANCER CASES HAS MORE THAN DOUBLED AROUND THE WORLD IN THE LAST THREE DECADES, WITH HIGHEST INCREASES OBSERVED IN LOW- AND MIDDLE-INCOME COUNTRIES. THESE TRENDS ARE CONCERNING, WHICH IS WHY KOMEN WORKS TIRELESSLY TO PROVIDE SUPPORT TO BREAST HEALTH PROGRAMS WORLDWIDE. IT TAKES COLLABORATION AND STRONG PARTNERSHIPS TO MAKE A GLOBAL IMPACT. KOMEN STRIVES TO SERVE AS A "BRIDGE" - COLLABORATING WITH INTERNATIONAL NONPROFITS, CORPORATIONS, AND MINISTRIES OF HEALTH TO BRING TOGETHER PEOPLE AND ORGANIZATIONS TO DEVELOP PROGRAMS THAT ARE TAILORED TO THE SPECIFIC NEEDS OF THE COMMUNITY AND SENSITIVE TO CULTURAL DIFFERENCES. IN FY19, KOMEN'S GLOBAL PROGRAM AWARDED TEN GRANTS TO SUPPORT EDUCATION PROGRAMMING FOR PATIENTS AND FOR HEALTH PROFESSIONALS AND TO REDUCE BARRIERS TO BREAST CANCER CARE IN CHINA, COLOMBIA, MEXICO, PANAMA, AND ZAMBIA. PUBLIC POLICY AND ADVOCACY SUSAN G. KOMEN IS COMMITTED TO DOING EVERYTHING WE CAN TO SERVE MORE THAN 260,000 WOMEN AND MEN IN THE UNITED STATES WHO WILL BE DIAGNOSED WITH BREAST CANCER THIS YEAR, THE MORE THAN 150,000 WHO ARE CURRENTLY LIVING WITH INCURABLE BREAST CANCER, AND TO SAVE THE MORE THAN 42,000 WOMEN AND MEN WHO WILL LOSE THEIR LIVES IN 2019. THIS INCLUDES MOBILIZING THE VOICE OF EVERYONE IMPACTED BY THE DISEASE TO IMPROVE OUTCOMES AND SAVE LIVES THROUGH SOUND PUBLIC POLICY. ONLY THROUGH INFORMED GOVERNMENT ACTION CAN WE MAKE THE BROAD, SYSTEMIC AND LASTING CHANGE WE NEED TO HELP US ACHIEVE OUR BOLD GOAL OF REDUCING THE CURRENT NUMBER OF BREAST CANCER DEATHS BY 50% IN THE U.S. BY 2026. KOMEN WORKS TO ENSURE THAT THE FIGHT AGAINST BREAST CANCER IS A PRIORITY AMONG POLICYMAKERS IN WASHINGTON, D.C., AND EVERY STATE CAPITOL ACROSS THE COUNTRY. EVERY TWO YEARS, THROUGH A TRANSPARENT, BROAD-BASED AND INTENSIVE VETTING AND SELECTION PROCESS, KOMEN WORKS TO IDENTIFY THE POLICY ISSUES WITH THE GREATEST POTENTIAL MISSION IMPACT. THIS PROCESS INCLUDES COLLECTING FEEDBACK FROM KOMEN AFFILIATES FROM ACROSS THE COUNTRY; ADVISORY GROUPS INCLUDING ADVOCATES IN SCIENCE (AIS) AND KOMEN SCHOLARS; REPRESENTATIVES FROM THE METASTATIC BREAST CANCER COMMUNITY AND KOMEN'S AFRICAN AMERICAN HEALTH EQUITY INITIATIVE; AND OTHER STAKEHOLDERS WITH A VESTED INTEREST IN BREAST CANCER-RELATED ISSUES. THE SELECTED ISSUES ARE THE BASIS FOR KOMEN'S STATE AND FEDERAL ADVOCACY. KOMEN'S 2018-2019 ADVOCACY PRIORITIES INCLUDED: SUPPORTING EXPANDED FEDERAL FUNDING FOR BREAST CANCER RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH (NIH) AND THE DEPARTMENT OF DEFENSE (DOD); SUPPORTING STATE AND FEDERAL FUNDING FOR THE CENTERS FOR DISEASE CONTROL AND PREVENTION'S (CDC) NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM (NBCCEDP); ADVOCATING FOR STATE AND FEDERAL POLICIES TO IMPROVE INSURANCE COVERAGE OF BREAST CANCER TREATMENTS, INCLUDING THOSE THAT WOULD REQUIRE ORAL PARITY, PRECLUDE SPECIALTY TIERS AND PREVENT STEP THERAPY PROTOCOLS; ADVOCATING FOR STATE AND FEDERAL POLICIES TO REDUCE OR ELIMINATE OUT-OF-POCKET COSTS FOR MEDICALLY NECESSARY DIAGNOSTIC IMAGING; AND EVALUATING STATE AND FEDERAL POLICIES TO INCREASE PUBLIC ACCESS TO INFORMATION ABOUT AND PARTICIPATION IN CLINICAL TRIALS FOR ALL PATIENT POPULATIONS. IN ADDITION TO THE STATE AND FEDERAL WORK ON OUR 2018-2019 ADVOCACY PRIORITIES, KOMEN CONTINUED OUR EFFORTS TO ENSURE EVERY BREAST CANCER PATIENT AND SURVIVOR HAS ACCESS TO AFFORDABLE, QUALITY HEALTH INSURANCE AND CARE. KOMEN ALSO ENGAGED ON ISSUES RELATED TO BREAST DENSITY, COMPASSIONATE USE, GENETIC TESTING, LYMPHEDEMA, PALLIATIVE CARE AND SURVIVORSHIP. KOMEN DEVELOPED AND IMPLEMENTED ADVOCACY CAMPAIGNS TO ENCOURAGE LAWMAKERS AND AGENCY OFFICIALS TO SUPPORT AND IMPLEMENT PROGRAMS THAT WOULD ADVANCE OUR PRIORITY ISSUES AND ADDITIONAL POLICY AREAS TO ACHIEVE KOMEN'S BOLD GOAL. KOMEN CONTINUED TO RECRUIT AND ENGAGE ADVOCATES TO FURTHER STRENGTHEN ITS GRASSROOTS ADVOCACY NETWORK. SCREENING AND PATIENT NAVIGATION GETTING REGULAR SCREENING TESTS, ALONG WITH EFFECTIVE AND QUALITY TREATMENT IF DIAGNOSED, LOWERS THE RISK OF DYING FROM BREAST CANCER. SCREENING TESTS CAN FIND BREAST CANCER EARLY, WHEN CHANCES FOR SURVIVAL ARE HIGHEST. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL - A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM. EVIDENCE SHOWS NAVIGATION IMPROVES ADHERENCE TO SCREENING RECOMMENDATIONS, AND THUS IMPROVES OVERALL OUTCOMES. KOMEN SUPPORTS FREE AND LOW-COST SCREENING PROGRAMS IN UNDERSERVED COMMUNITIES THAT HELP NAVIGATE PEOPLE TO QUALITY CARE, AND/OR PROVIDE COVERAGE FOR SCREENING SERVICES TO PEOPLE WITHOUT HEALTH INSURANCE, OR THOSE WITH HIGH CO-PAYS AND DEDUCTIBLES THAT MAKE SCREENING TOO COSTLY. IN FY19, KOMEN AWARDED ONE SCREENING COMMUNITY GRANT TO BREAST CARE FOR WASHINGTON, TO DEVELOP A MOBILE MAMMOGRAPHY PROJECT TO INCREASE ACCESS TO QUALITY SCREENING AND NAVIGATE WOMEN INTO DIAGNOSIS AND TREATMENT. TREATMENT AND PATIENT NAVIGATION BARRIERS TO QUALITY CARE ARE OFTEN ASSOCIATED WITH POOR BREAST CANCER OUTCOMES AND RESULTANT CANCER DISPARITIES AMONG SPECIFIC POPULATION GROUPS. ACCORDING TO QUALITATIVE DATA COLLECTED FROM ACROSS KOMEN'S AFFILIATE NETWORK, THE MOST COMMON BARRIERS TO QUALITY CARE IN THE UNITED STATES INCLUDE: (1) AVAILABILITY OF LOCAL SERVICES; (2) BREAST CANCER EDUCATION; (3) CULTURAL/LANGUAGE; (4) FEAR; (5) FINANCIAL; (6) INSURANCE; (7) TRANSPORTATION. PATIENT NAVIGATION IS A PROCESS BY WHICH AN INDIVIDUAL - A PATIENT NAVIGATOR - GUIDES PATIENTS THROUGH AND AROUND BARRIERS IN THE COMPLEX CANCER CARE SYSTEM TO ENSURE TIMELY DIAGNOSIS AND TREATMENT. EVIDENCE SHOWS PATIENT NAVIGATION IMPROVES ADHERENCE TO TREATMENT RECOMMENDATIONS, RESULTING IN IMPROVED OUTCOMES. IN FY19, KOMEN FUNDED THREE NONPROFIT ORGANIZATIONS IN SUPPORT OF PROGRAMS TO REDUCE STRUCTURAL, PERSONAL, SOCIOCULTURAL, AND FINANCIAL BARRIERS TO CARE, AND PROVIDE PATIENT NAVIGATION SERVICES FOR UNDERSERVED COMMUNITIES IN THE WASHINGTON, D.C. METRO AREA, SPECIFICALLY WARDS 2, 5, 7, AND 8, AND ALEXANDRIA CITY, VA. KOMEN'S TREATMENT ASSISTANCE PROGRAM, ADMINISTERED BY CANCERCARE, AIMS TO HELP WOMEN AND MEN IN BREAST CANCER TREATMENT WHO ARE FACING FINANCIAL CHALLENGES STAY IN TREATMENT BY PROVIDING LIMITED FINANCIAL ASSISTANCE, EDUCATION, AND SUPPORT SERVICES. FINANCIAL ASSISTANCE IS GRANTED TO UNDERSERVED, UNDERINSURED OR UNINSURED WOMEN AND MEN ACROSS THE COUNTRY UNDERGOING BREAST CANCER TREATMENT WHO MEET PRE-DETERMINED ELIGIBILITY CRITERIA. THIS PROGRAM PROVIDES FINANCIAL ASSISTANCE FOR TREATMENT-RELATED COSTS, INCLUDING TRANSPORTATION TO AND FROM TREATMENT, CHILD/ELDER CARE, HOME CARE, ORAL PAIN/ANTI-NAUSEA MEDICATIONS, ORAL CHEMOTHERAPY/HORMONE THERAPY, LYMPHEDEMA CARE/SUPPLIES, PALLIATIVE CARE, AND DURABLE MEDICAL EQUIPMENT. WE SERVED MORE THAN 3500 PEOPLE THROUGH THIS PROGRAM IN FY19. EXECUTIVE COMMITTEE FORM 990, PART VI, LINE 1A THE ORGANIZATION'S BYLAWS PROVIDE FOR AN EXECUTIVE COMMITTEE COMPRISED OF A MINIMUM OF FIVE MEMBERS INCLUDING THE BOARD CHAIR, THE PRESIDENT AND CHIEF EXECUTIVE OFFICER, AND ADDITIONAL BOARD MEMBERS, AS RECOMMENDED BY THE GOVERNANCE COMMITTEE AND APPOINTED BY THE BOARD OF DIRECTORS. MEMBERS OF THE EXECUTIVE COMMITTEE MUST EITHER BE DIRECTORS OF THE ORGANIZATION OR THE PRESIDENT AND CHIEF EXECUTIVE OFFICER. THE BYLAWS PROVIDE THE EXECUTIVE COMMITTEE WITH THE AUTHORITY TO: (A) APPOINT MEMBERS TO NON-STANDING COMMITTEES OF THE ORGANIZATION, AND NAME CHAIRS OF SUCH COMMITTEES; (B) AUTHORIZE UNBUDGETED DISBURSEMENTS BY THE ORGANIZATION IN ACCORDANCE WITH THE SPECIFIC EXPENDITURE AUTHORITY PRESCRIBED BY THE BOARD OF DIRECTORS; (C) EMPLOY AGENTS; AND (D) CARRY INTO EXECUTION SUCH OTHER MEASURES AS IT DETERMINES WILL PROMOTE THE PURPOSE OF THE ORGANIZATION. THE COMMITTEE ALSO MAY EXERCISE, WHEN THE BOARD IS NOT IN SESSION, ALL OF THE AUTHORITY OF THE BOARD IN THE MANAGEMENT OF THE BUSINESS AND AFFAIRS OF THE ORGANIZATION WITH CERTAIN EXCEPTIONS SUCH AS REPEALING ANY BOARD RESOLUTIONS, AMENDING THE ORGANIZATION'S ARTICLES OR BYLAWS, OR MERGING OR DISSOLVING THE ORGANIZATION. THIS DELEGATION DOES NOT RELIEVE THE BOARD OF ANY OF ITS RESPONSIBILITIES IMPOSED BY LAW, AND THE COMMITTEE ENDEAVORS TO LIMIT ITS EXERCISE OF AUTHORITY TO TIME SENSITIVE ISSUES. DESCRIBE THE PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW 990 FORM 990, PART VI, QUESTION 11B MANAGEMENT PREPARES THE MATERIALS FOR THE FORM 990, WITH THE ASSISTANCE OF AND REVIEW BY EXTERNAL ACCOUNTANTS. SENIOR LEVEL MANAGEMENT REVIEW AND COMMENT ON THE FINAL DRAFT OF THE FORM 990 FOR SUBSEQUENT PRESENTATION TO THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWS, MAKES RECOMMENDATIONS, AND APPROVES THE FORM 990 FOR PRESENTATION TO THE BOARD OF DIRECTORS. THEREAFTER, THE BOARD OF DIRECTORS REVIEWS AND APPROVES THE FORM 990 PRIOR TO FILING. DESCRIPTION OF PROCESS TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST FORM 990, PART VI, QUESTION 12C Komen's Conflict of Interest Policy requires every board member, officer, committee member, advisory board member, and employee to avoid conflicts of Interest. It also requires these persons to report any actual and/or potential conflicts of interest as soon as possible. Reports are reviewed by the General Counsel's office and/or Internal Audit, and appropriate action is taken pursuant to the Conflict of Interest Policy. Further, Komen produces an annual survey requiring all board members, officers, committee members, advisory board members, and employees to review the Conflict of Interest Policy and disclose any additional actual/potential conflicts of interest. These annual disclosures are reviewed in the same manner. The Audit Committee of the Board of Directors receives, and reviews all reported actual and potential conflicts of interest and the related action to address them. OFFICES & POSITIONS FOR WHICH PROCESS WAS USED, & YEAR PROCESS WAS BEGUN FORM 990, PART VI, QUESTION 15A & 15B THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTS THE BOARD IN OVERSEEING COMPENSATION POLICIES AND BEST PRACTICES. RESPONSIBILITIES INCLUDE OVERSIGHT OF THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER; THE RANGE OF COMPENSATION LEVELS FOR THE ORGANIZATION'S OTHER OFFICERS, DISQUALIFIED PERSONS, AND OTHER KEY EMPLOYEES; GRANTING THE CHIEF EXECUTIVE OFFICER WITH THE AUTHORITY TO DETERMINE COMPENSATION LEVELS WITHIN AN APPROVED RANGE; AND ANY INCENTIVE/BONUS COMPENSATION PROGRAMS, IF APPROVED. THE CURRENT POLICY WAS ADOPTED IN 2010. A FORMAL COMPENSATION POLICY GOVERNS PAY PRACTICES. PERIODICALLY, ALL POSITIONS IN THE ORGANIZATION ARE REVIEWED AGAINST EXTERNAL MARKET DATA BY ENGAGING INDEPENDENT EXPERTS OR ACQUIRING UPDATED MARKET DATA TO CONDUCT THE BENCHMARKING PROCESS. COMPENSATION IS THEN BASED UPON COMPARABLE MARKET RATES OF PAY WITH CONSIDERATION FOR INTERNAL EQUITY AND THE FINANCIAL POSITION OF THE ORGANIZATION. BENCHMARKING WAS CONDUCTED FOR THE CHIEF EXECUTIVE OFFICER AND ALL EXECUTIVE TEAM MEMBERS' COMPENSATION TO EXTERNAL MARKET DATA IN 2019, TO ENSURE MARKET ALIGNMENT. KOMEN PROVIDES SALARY INCREASES, PROMOTIONS AND OTHER FORMS OF COMPENSATION WITHOUT REGARD TO RACE, COLOR, RELIGION, GENDER, NATIONAL ORIGIN, DISABILITY, VETERAN STATUS OR SEXUAL ORIENTATION. AVAIL OF GOV DOCS, CONFLICT OF INTEREST POLICY, & FIN STMTS TO GEN PUBLIC FORM 990, PART VI, QUESTION 19 KOMEN'S FINANCIAL STATEMENTS AND THE FORM 990 ARE PUBLICLY AVAILABLE ON OUR WEBSITE. THE CERTIFICATE OF FORMATION IS AVAILABLE FROM THE TEXAS SECRETARY OF STATE AND OTHER GOVERNING DOCUMENTS ARE MADE AVAILABLE AS REQUIRED BY STATE LAW. FORM 1023 AND THE CONFLICT OF INTEREST POLICY ARE NOT PUBLISHED ONLINE BUT ARE AVAILABLE TO THE PUBLIC UPON REQUEST. ADDITIONAL DETAIL ON EVENT PRODUCTION EXPENSES INCLUDED ON OTHER EXP FORM 990, PART IX, LINE 24 KOMEN PAYS 50% OF THE COST OF ALL T-SHIRTS FOR THE 111 SUSAN G. KOMEN RACE FOR THE CURE AND MORE THAN PINK WALK EVENTS CONDUCTED BY THE KOMEN AFFILIATES DURING THE FISCAL YEAR. ACCOUNTS RECEIVABLE FORM 990, PART X, LINE 4 The beginning of year amount for accounts receivable was determined by adding the amount of accounts receivable with pledges and grants receivable, net (line 3A). OTHER CHANGES IN NET ASSETS OR FUND BALANCES FORM 990, PART XI, LINE 9 RESCINDED GRANTS $1,681,546 UTAH FIELD OFFICE ADJUSTMENT $717 ----------------- TOTAL $1,682,263 ==========